PLIANT THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
Phone
650-481-6770
Fiscal Year End
1231
EIN
474272481
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 10-K Annual financial report | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 9, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
Annual Reports
10-K
March 11, 2026
- Advancing PLN-74809 into Phase 2 trials for IPF and PSC, with data readouts anticipated in late 2025.
- Strategic collaboration with Novartis effective in 2025, providing significant validation and potential non-dilutive funding.
Insider Trading
SELL
4 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.